NCT00192387已完成2 期
A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate Viral Shedding in Healthy Children (6 Mos and Less Than or Equal to 18 Months of Age) Vaccinated With Two Doses of Liquid Formulation of Influenza Virus Vaccine, Live Cold Adapted (CAIV-T)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Measurement of influenza-specific immune response following receipt of CAIV-T.
研究概览
简要总结
The primary objective of this study was to determine the proportion of subjects, seronegative to all three strains of influenza, as defined by a serum hemagglutination inhibition antibodies (HAI) antibody titer of <1:10, who shed each vaccine virus strain following a single dose of CAIV-T.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 6 Months 至 18 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •children at least 6 months of age and less than or equal to 18 months of age at the time of enrollment, and in good health as determined by medical history, physical examination, and clinical judgment;
- •whose parent/legal guardian has provided written informed consent after the nature of the study has been explained;
- •who, along with their parent or legal guardian, will be available for the two month duration of the trial (from enrollment to study completion).
排除标准
- •whose parents or legal guardians are perceived to be unavailable or difficult to contact for evaluation or study visits during the study period;
- •with any serious chronic disease (e.g., with signs of cardiac or renal failure or severe malnutrition), including progressive neurological disease;
- •with Down's syndrome or other known cytogenetic disorders;
- •with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids; intranasal steroids or cytotoxic agents;
- •have an immunosuppressed or an immunocompromised individual living in the same household;
- •with a documented history of hypersensitivity to egg or egg protein or any other component of the study vaccine or placebo;
- •who, at anytime prior to study enrollment, receives any influenza vaccine (commercial or investigational);
- •with any medical conditions that in the opinion of the investigator might interfere with interpretation of the study results.
- •Note: A pregnant household member is not considered a contraindication to enrollment.
结局指标
主要结局
Measurement of influenza-specific immune response following receipt of CAIV-T.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
不适用
A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in Combinationwith Pegasys and Copegus for 12 or 24 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Na?ve Patients with Chronic Hepatitis C Genotype 1 Virus Infection. - NDChronic Hepatitis C (CHC) Genotype 1MedDRA version: 12.0Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2009-009608-38-ITF.Hoffmann-La Roche300
进行中（未招募）
1 期
A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Copegus for 12 or 24 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus InfectioEUCTR2009-009608-38-FRF.Hoffmann-La Roche300
进行中（未招募）
不适用
A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Copegus for 12 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus InfectioEUCTR2009-009608-38-ATF.Hoffmann-La Roche300
进行中（未招募）
不适用
A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Copegus for 12 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus InfectioChronic Hepatitis C Genotype 1 Virus Infection (Treatment-Naive Patients)MedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2009-009608-38-DEF.Hoffmann-La Roche300
进行中（未招募）
1 期
ASC-201 Plus Trifluridine/Tipiracil for the Treatment of Advanced Gastric CancerAdvanced Gastric Cancer.MedDRA version: 20.0Level: SOCClassification code 10017947Term: Gastrointestinal disordersSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-003799-15-ESAscelia Pharma AB139